Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEPHB4-HSA in relapsed or refractory acute leukemia
NCT03519984Phase 1Terminated
- Sponsor
- University of Southern California
- Start
- May 2018
- Primary completion
- Nov 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sephb4-hsa in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 2 more, sponsored by University of Southern California. Started May 2018; status: terminated.
02
Drugs
sephb4-hsa
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT03519984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519984.